Clinical Trials on Unresected Stage IIIB to IVM1c Melanoma in Spain

Total 11 results

Amgen

Completed

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma (TVEC-325)

Unresected Stage IIIb to IVM1c Melanoma

France, Poland, Italy, Russian Federation, Netherlands, Spain, United States, Austria, Belgium, United Kingdom, Germany, Hungary, Greece
Amgen

Completed

Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma

United States, Poland, France, Russian Federation, Spain, Australia, Greece, Switzerland, Brazil
Grupo Español Multidisciplinar de Melanoma
GlaxoSmithKline

Completed

Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain (DEIS)

Malignant Melanoma Stage IV | Malignant Melanoma Stage IIIc

Spain
Hospital Universitario Virgen Macarena

Recruiting

Conservative Nodal Surgery (Node-picking) of Patients With Stage III Melanoma With Low-burden of Nodal Disease (MELCONSURG MULTICENTRE COHORT)

Melanoma Stage III

Spain
Grupo Español Multidisciplinar de Melanoma

Recruiting

Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain (GEM-1801)

Advanced Cancer | Melanoma Stage Iv | Melanoma Stage Iii

Spain
Philogen S.p.A.

Recruiting

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients (NeoDREAM)

Melanoma Stage IIIB/C

Spain, United States, Switzerland
BioNTech SE
Regeneron Pharmaceuticals

Active, not recruiting

Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

Unresectable Melanoma | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, Italy, Australia, United Kingdom, Poland
European Organisation for Research and Treatment...

Active, not recruiting

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)

Stage IV Melanoma | Unresectable Stage III Melanoma

France, Denmark, Spain, Finland, Italy, Germany, Poland, United Kingdom, Netherlands
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, France, Australia, Italy, Greece, Israel, Russian Federation, New Zealand, Austria, United Kingdom, Netherlands, Portugal, Poland, Czechia, Romania
Bristol-Myers Squibb

Completed

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

High Risk Stage III Melanoma

Italy, Poland, United Kingdom, United States, Netherlands, Spain, Australia, France, Germany, Canada, Russian Federation, Belgium, Norway, Switzerland, Sweden, Finland, Austria, Denmark, Czechia
OncoHost Ltd.

Recruiting

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments (PROPHETIC)

Stage IV Non-small Cell Lung Cancer | Stage III Malignant Melanoma | Stage IV Small Cell Lung Cancer | Stage IV Malignant Melanoma

United States, Israel, United Kingdom, Germany, Spain

Clinical Trials on Unresected Stage IIIB to IVM1c Melanoma in Spain

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations